Liu Xiu-Mei, DU Li-Ping, Liu Bao
Department of Pharmacy,People's Hospital of Zhengzhou,Zhengzhou 450003,China.
Department of Pharmacy,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2020 Aug 30;42(4):562-565. doi: 10.3881/j.issn.1000-503X.11423.
Oral anticoagulants play an important role in the prevention and treatment of thromboembolic diseases.Warfarin,a traditional oral anticoagulant,is limited in clinical use due to its limitations such as narrow therapeutic window and requirements on frequent monitoring and dose adjustment.Direct oral anticoagulants(DOACs)such as dabigatran,rivaroxaban,apixaban,and edoxaban are increasingly used to prevent and treat venous thrombosis or thrombus formation.However,recent studies have documented inter-individual variability in plasma drug levels of DOACs.This article summarizes the recent advances in the pharmacogenomics of DOACs.
口服抗凝剂在血栓栓塞性疾病的预防和治疗中发挥着重要作用。华法林作为一种传统的口服抗凝剂，由于其治疗窗窄、需要频繁监测和调整剂量等局限性，在临床应用中受到限制。达比加群、利伐沙班、阿哌沙班和依度沙班等直接口服抗凝剂（DOACs）越来越多地用于预防和治疗静脉血栓形成或血栓。然而，最近的研究记录了DOACs血浆药物水平的个体间差异。本文总结了DOACs药物基因组学的最新进展。
